Does Takayasu arteritis differ between children and adolescents? Insights from a Russian multicenter cohort

Table 5 Baseline characteristics of patients included in and excluded from outcome analysis

Parameter	Outcome analysis (n = 62)	Excluded (n = 17)	P value
Disease duration, months, median	49.00 [26.00; 65.00]	9.50 [3.25; 15.25]	< 0.001
Time from first symptoms to diagnosis, months, median	7.00 [2.00; 20.00]	9.50 [2.25; 14.25]	0.930
Follow-up duration after diagnosis, months, median	30.00 [19.50; 44.25]	1.00 [1.00; 2.00]	< 0.001
Age at onset, years, median	11.00 [9.00; 14.00]	11.00 [8.00; 13.00]	0.647
ITAS2010 at onset, median	7.00 [5.00; 9.00]	5.00 [4.00; 7.00]	0.173
ITAS.A at onset, median	11.00 [9.00; 14.00]	7.00 [5.00; 11.00]	0.015
CRP at onset, mg/L, median	40.00 [15.73; 99.25]	4.90 [1.23; 36.75]	0.001
ESR at onset, mm/hour	50.90 (22.06)	36.56 (31.49)	0.040
bDMARD use	38 (61.3)	2 (11.8)	0.001
Female sex	51 (82.3)	11 (64.7)	0.197
Surgical intervention at diagnosis	7 (11.3)	4 (23.5)	0.131

Data are presented as median (interquartile range), mean (SD), or n (%). IQR: Interquartile range; bDMARD: Biologic disease-modifying antirheumatic drugs; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein.